Initial tests on mice showed the hybrid virus was very efficient: the gene it carried was active in 24 per cent of
airway cells after two months, a far better proportion than achieved by other delivery methods (New Scientist, 10 March 2001, p 19).
Not exact matches
«We looked microscopically at the lung tissue of horses that died during or just
after races, and quantified the inflammatory
cells within their
airways,» said Prof. Luis Arroyo, Department of Clinical Studies.
They found that infection of the narrowest
airways of the lung by PIV3 alone caused moderate levels of inflammation, but
after infection by PIV3 expressing RSV NS2, the epithelial
cells lining the narrow
airways were shed rapidly into the
airway lumen.
One of the major parameters was the safety of these agents in the respiratory
airways and lung parenchyma, since several of these agents are known to cause adverse effects.23 The main adverse effects observed were cough, transient fever and transient decrease in the respiratory functions
after the aerosol administration.8, 19, 20 Moreover; it has been observed that excessive deposition of these agents in one site of the respiratory system can induce non-specific side effects in the form of pulmonary edema as observed with many other drugs.16 These side effects were milder when a premedication with bronchodilators and inhaled corticosteroids were administered.8, 19, 20 Until now no long term trial (> 9 months) has been performed since all patients included in previous studies had stage IV non-small
cell lung cancer (NSCLC).